Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01811667
Other study ID # vasca-LM
Secondary ID
Status Completed
Phase Phase 3
First received October 5, 2012
Last updated April 13, 2016
Start date May 2012
Est. completion date January 2016

Study information

Verified date April 2016
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

The phosphatidylinositol 3-kinase (PI3Kinase)/Protein Kinase B (AKT)/mammalian target of rapamycin (mTor) pathway plays a role on the development and the lymphatic-vascular organisations.

The investigators want to study the efficacy and the safety of Rapamycin, an mTor inhibitor.


Description:

The complex vascular malformations induce chronical pains and organic dysfunctions causing significant morbidity and mortality. Therefore, the investigators need to establish guidelines in order to treat these pathologies. Standard treatments such as surgery or interventional radiology are of limited efficacy and related to a high level of recurrences as well as complications. Recent preclinical studies have shown the important role of the PI3Kinase/AKT/mTor pathway on the development and the lymphatic-vascular organisations suggesting an appealing therapeutic target to treat patients with complex vascular malformations.

The aim of this clinical study is to prospectively evaluate the efficacy and the safety of the Rapamycin, an mTOR inhibitor, to treat children and adults with microcystic lymphatic malformations, general lymphatics abnormalities (GLA) or complex vascular malformations for which conventional therapies as surgery or sclerotherapy are ineffective or associated with high risk of important complications.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Both
Age group N/A to 70 Years
Eligibility Inclusion Criteria:

- Patients with complex vascular abnormalities to be threat by a systemic therapy

- Patients must have adequate liver function (LDL-cholesterol, triglycerides,…)

- Patients must have adequate organ function: neutrophils >1500/mm³, Hb > 8,0 g et platelets> 50.000/mm³ (no platelets limits for the Kasabach Merritt syndrome)

- Patients must have adequate renal function(normal creatinin depending on the age), clearance > 70 ml/min/1.73m² and Urin Protein Creatinine ratio <0.3 g.

- Karnofsky or Landry > 50

Exclusion Criteria:

- Dental equipments or prosthesis interfering onto a radiological examen

- Other uncontrolled medical condition (uncontrolled diabetes, hypertension…)

- Concomitant drugs such as inhibitors/inducers of cytochrome P450 3A4 (CYP3A4)

- Immunocompromised patients, including known seropositivity for HIV

- Digestive problems modifying the absorption of Rapamycin (gastric tube feeding accepted)

- Pregnant or nursing (lactating) women

- Prior treatment with phosphatidylinositol 3-kinase (PI3K) and/or mTOR inhibitors

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Sirolimus


Locations

Country Name City State
Belgium Cliniques universitaires Saint-Luc Brussels

Sponsors (1)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time of duration of the treatment.(Efficacy) up to 12 months No
Secondary The number of adverse events observed With Common Toxicity Criteria for Adverse Effects version 3 up to 12 months Yes
See also
  Status Clinical Trial Phase
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Active, not recruiting NCT02973126 - Heartflow (AFFECTS) Phase 3
Withdrawn NCT00844935 - Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients N/A
Completed NCT01410487 - Effects of Weight Loss on Cardio-respiratory Function N/A
Withdrawn NCT00807274 - Renal Function in Adults With Congenital Heart Disease. N/A
Withdrawn NCT00468702 - Postoperative Canadian Oral Anticoagulation Self-management (Post-COAGS) Trial N/A
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Completed NCT03758092 - Cardiovascular Screening in Infants Born Small for Gestational Age
Completed NCT03545672 - Early Identification of Myocardial Impairment in PBC
Recruiting NCT06091384 - Inspiratory Muscle Strength Training in Post-Covid Syndrome N/A
Completed NCT04586894 - Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors
Completed NCT03826914 - The Effects of the Dietary Supplement CardioFlex Q10 on Reducing Cardiovascular Disease Risk Factors in Adults N/A
Not yet recruiting NCT05624255 - Correlating the Measure of Retinal Vascular Density Through Angio-OCT With Calcium Score N/A
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Completed NCT01820702 - Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation N/A
Recruiting NCT04766203 - Relative Energy Deficiency in Sport Multicenter Study N/A
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Completed NCT02616913 - Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects N/A
Completed NCT00901394 - Vitamin B12 and Folate Administration on Homocysteine Concentrations After Nitrous Oxide Anesthesia N/A
Completed NCT03354689 - Transcutaneous Electrical Nerve Stimulation and Cardiac Sympathetic Overdrive in Heart Failure